Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Haegarda Generic Name & Formulations
Legal Class
Rx
General Description
C1 esterase inhibitor (human) 2000 IU, 3000 IU; lyophilized pwd for SC inj after reconstitution; preservative-free.
Pharmacological Class
C1 inhibitor.
How Supplied
Single-use vial—1
Manufacturer
Generic Availability
NO
Haegarda Indications
Indications
Routine prophylaxis to prevent hereditary angioedema (HAE) attacks in patients ≥6yrs.
Haegarda Dosage and Administration
Adults and Children
<6yrs: not established. Rotate inj sites. Give by SC inj (eg, abdominal area, other SC sites). ≥6yrs: 60 IU/kg twice weekly (every 3 or 4 days).
Haegarda Contraindications
Not Applicable
Haegarda Boxed Warnings
Not Applicable
Haegarda Warnings/Precautions
Warnings/Precautions
Discontinue and treat if severe hypersensitivity reactions occur. Have epinephrine inj available. Risk of thromboembolism events. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Elderly. Pregnancy. Nursing mothers.
Haegarda Pharmacokinetics
See Literature
Haegarda Interactions
Not Applicable
Haegarda Adverse Reactions
Adverse Reactions
Inj site reaction, hypersensitivity, nasopharyngitis, dizziness.
Haegarda Clinical Trials
See Literature
Haegarda Note
Notes
To report infections that may have been transmitted by Haegarda, call (866) 915-6958.
Haegarda Patient Counseling
See Literature
Images
